Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy

results from retrospective, multicenter data

Chang Wook Jeong, Minyong Kang, Seung Il Jung, Tae Hwan Kim, Sung Woo Park, Jae Young Joung, Seong Soo Jeon, Jun Hyuk Hong, Ji Youl Lee, Byungha Chung, Hanjong Ahn, Choung Soo Kim, Dong Deuk Kwon, Cheol Kwak

Research output: Contribution to journalArticle

Abstract

Background: Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. Methods: We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival. Results: The median age of the patients was 71 years (interquartile range, 64–75 years). The proportion of patients in a grade group ≥4 was 77.6%. The rate of concomitant ADT was 29.3%, and the all-cause mortality rate was 27.1% (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjusting for confounding factors, concomitant ADT was still associated with longer overall survival (hazard ratio, 0.35; 95% confidence interval, 0.17–0.72). Conclusion: Concomitant ADT during enzalutamide treatment may improve the survival of patients with mCRPC following chemotherapy.

Original languageEnglish
Pages (from-to)150-158
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume22
Issue number1
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Castration
Androgens
Prostatic Neoplasms
Drug Therapy
Survival
Therapeutics
Prostate-Specific Antigen
Disease-Free Survival
MDV 3100
Korea
Medical Records
Confidence Intervals
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology
  • Cancer Research

Cite this

Jeong, Chang Wook ; Kang, Minyong ; Il Jung, Seung ; Kim, Tae Hwan ; Park, Sung Woo ; Joung, Jae Young ; Jeon, Seong Soo ; Hong, Jun Hyuk ; Lee, Ji Youl ; Chung, Byungha ; Ahn, Hanjong ; Kim, Choung Soo ; Kwon, Dong Deuk ; Kwak, Cheol. / Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy : results from retrospective, multicenter data. In: Prostate Cancer and Prostatic Diseases. 2019 ; Vol. 22, No. 1. pp. 150-158.
@article{9d34f8487fc24345857be593baff1edc,
title = "Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data",
abstract = "Background: Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. Methods: We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival. Results: The median age of the patients was 71 years (interquartile range, 64–75 years). The proportion of patients in a grade group ≥4 was 77.6{\%}. The rate of concomitant ADT was 29.3{\%}, and the all-cause mortality rate was 27.1{\%} (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjusting for confounding factors, concomitant ADT was still associated with longer overall survival (hazard ratio, 0.35; 95{\%} confidence interval, 0.17–0.72). Conclusion: Concomitant ADT during enzalutamide treatment may improve the survival of patients with mCRPC following chemotherapy.",
author = "Jeong, {Chang Wook} and Minyong Kang and {Il Jung}, Seung and Kim, {Tae Hwan} and Park, {Sung Woo} and Joung, {Jae Young} and Jeon, {Seong Soo} and Hong, {Jun Hyuk} and Lee, {Ji Youl} and Byungha Chung and Hanjong Ahn and Kim, {Choung Soo} and Kwon, {Dong Deuk} and Cheol Kwak",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41391-018-0088-z",
language = "English",
volume = "22",
pages = "150--158",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy : results from retrospective, multicenter data. / Jeong, Chang Wook; Kang, Minyong; Il Jung, Seung; Kim, Tae Hwan; Park, Sung Woo; Joung, Jae Young; Jeon, Seong Soo; Hong, Jun Hyuk; Lee, Ji Youl; Chung, Byungha; Ahn, Hanjong; Kim, Choung Soo; Kwon, Dong Deuk; Kwak, Cheol.

In: Prostate Cancer and Prostatic Diseases, Vol. 22, No. 1, 01.03.2019, p. 150-158.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy

T2 - results from retrospective, multicenter data

AU - Jeong, Chang Wook

AU - Kang, Minyong

AU - Il Jung, Seung

AU - Kim, Tae Hwan

AU - Park, Sung Woo

AU - Joung, Jae Young

AU - Jeon, Seong Soo

AU - Hong, Jun Hyuk

AU - Lee, Ji Youl

AU - Chung, Byungha

AU - Ahn, Hanjong

AU - Kim, Choung Soo

AU - Kwon, Dong Deuk

AU - Kwak, Cheol

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. Methods: We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival. Results: The median age of the patients was 71 years (interquartile range, 64–75 years). The proportion of patients in a grade group ≥4 was 77.6%. The rate of concomitant ADT was 29.3%, and the all-cause mortality rate was 27.1% (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjusting for confounding factors, concomitant ADT was still associated with longer overall survival (hazard ratio, 0.35; 95% confidence interval, 0.17–0.72). Conclusion: Concomitant ADT during enzalutamide treatment may improve the survival of patients with mCRPC following chemotherapy.

AB - Background: Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. Methods: We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival. Results: The median age of the patients was 71 years (interquartile range, 64–75 years). The proportion of patients in a grade group ≥4 was 77.6%. The rate of concomitant ADT was 29.3%, and the all-cause mortality rate was 27.1% (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjusting for confounding factors, concomitant ADT was still associated with longer overall survival (hazard ratio, 0.35; 95% confidence interval, 0.17–0.72). Conclusion: Concomitant ADT during enzalutamide treatment may improve the survival of patients with mCRPC following chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85053457308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053457308&partnerID=8YFLogxK

U2 - 10.1038/s41391-018-0088-z

DO - 10.1038/s41391-018-0088-z

M3 - Article

VL - 22

SP - 150

EP - 158

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -